Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has seen a 5.1% increase in stock price, reaching 18.12 CNY per share, with a total market capitalization of 4.408 billion CNY as of February 24 [1] Group 1: Company Overview - Linuo Pharmaceutical Packaging was established on March 1, 2002, and went public on November 11, 2021 [1] - The company specializes in the research, production, and sales of specialty glass, focusing on the development and application of borosilicate glass [1] - The revenue composition of the company includes 57.02% from heat-resistant glass, 40.74% from pharmaceutical glass, and 2.24% from material sales and others [1] Group 2: Shareholder Information - YX Fund's YX Healthcare A (006274) has entered the top ten circulating shareholders of Linuo Pharmaceutical, holding 1.62 million shares, which is 0.68% of the circulating shares [2] - The fund has achieved a year-to-date return of 7.94% and a one-year return of 35.34% [2] - The fund manager, Xiao Shiyuan, has a tenure of 8 years and 251 days, with a total fund asset size of 2.069 billion CNY [2][4] Group 3: Fund Holdings - YX Fund's YX聚优 A (010469) has reduced its holdings in Linuo Pharmaceutical by 77,400 shares, now holding 1.1776 million shares, which constitutes 2.99% of the fund's net value [3] - The fund has a year-to-date return of 6.25% and a one-year return of 34.56% [3] - The fund manager, Xiao Shiyuan, has a total asset size of 2.069 billion CNY [4]

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Linuo Pharmaceutical Packaging Co., Ltd., indicating a significant increase in financing activities and a decrease in revenue and net profit [1][2]. Group 2 - On January 22, Linuo Pharmaceutical's stock rose by 1.58%, with a trading volume of 95.04 million yuan. The financing buy-in amount for the day was 20.23 million yuan, while the net financing buy-in reached 12.20 million yuan [1]. - As of January 22, the total balance of margin trading for Linuo Pharmaceutical was 195 million yuan, accounting for 4.36% of its market capitalization, indicating a high level of financing activity [1]. - The company reported a total revenue of 721 million yuan for the period from January to September 2025, reflecting a year-on-year decrease of 13.22%. The net profit attributable to shareholders was 50.88 million yuan, down 27.80% year-on-year [2]. - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2]. - As of September 30, 2025, the number of shareholders increased to 17,600, a rise of 58.60%, while the average circulating shares per person decreased by 36.94% to 13,571 shares [2].

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in stock performance and financial metrics, with a notable increase in stock price year-to-date, but a decline in revenue and net profit for the first nine months of 2025 [1][2]. Financial Performance - As of September 30, 2025, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22% [2]. - The net profit attributable to shareholders for the same period was 50.88 million yuan, reflecting a year-on-year decline of 27.80% [2]. - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [3]. Stock Market Activity - On December 29, Linuo Pharmaceutical's stock rose by 2.11%, reaching 17.90 yuan per share, with a trading volume of 58.95 million yuan and a turnover rate of 1.40% [1]. - The company's market capitalization stands at 4.279 billion yuan [1]. - Year-to-date, the stock price has increased by 19.95%, with a 1.94% rise over the last five trading days, 5.05% over the last 20 days, and 3.71% over the last 60 days [1]. Shareholder Composition - The number of shareholders increased to 17,600 as of September 30, 2025, marking a 58.60% rise from the previous period [2]. - The average number of tradable shares per shareholder decreased by 36.94% to 13,571 shares [2]. - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed Fund and Green High Dividend Preferred Mixed Fund, among others [3].

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. experienced a decline in stock price and financial performance, with significant changes in financing and shareholder structure [1][2]. Financing Summary - On December 23, Linuo Pharmaceutical's stock fell by 1.48%, with a trading volume of 41.78 million yuan. The financing buy-in amount was 3.74 million yuan, while the financing repayment was 6.19 million yuan, resulting in a net financing outflow of 2.45 million yuan [1]. - As of December 23, the total financing and securities lending balance for Linuo Pharmaceutical was 151 million yuan, accounting for 3.65% of its market capitalization, indicating a high level compared to the past year [1]. - The company had no shares sold short or repaid on December 23, with a securities lending balance of 29,240 yuan, which is above the 90th percentile for the past year [1]. Financial Performance Summary - For the period from January to September 2025, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2]. - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2]. Shareholder Structure Summary - As of September 30, 2025, the number of shareholders for Linuo Pharmaceutical increased to 17,600, a rise of 58.60% from the previous period, while the average number of circulating shares per shareholder decreased by 36.94% to 13,571 shares [2]. - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B, holding 3.8 million shares, and Green High Dividend Preferred Mixed A, holding 3.14 million shares, both ranking among the top ten circulating shareholders [2].

Core Insights - Linuo Pharmaceutical Packaging Co., Ltd. experienced a slight increase in stock price by 0.64% on November 12, with a trading volume of 66.55 million yuan [1] - The company reported a financing buy-in amount of 3.93 million yuan and a financing repayment of 8.51 million yuan on the same day, resulting in a net financing buy of -4.58 million yuan [1] - As of November 12, the total financing and securities lending balance for Linuo Pharmaceutical was 130 million yuan, which accounts for 3.12% of its circulating market value [1] Financing Overview - On November 12, Linuo Pharmaceutical had a financing buy-in of 3.93 million yuan, with a current financing balance of 130 million yuan, exceeding the 60th percentile level over the past year [1] - The company had no securities lending activity on November 12, with a securities lending balance of 0.00 shares, indicating a high level of inactivity in this area [1] Company Profile - Linuo Pharmaceutical, established on March 1, 2002, and listed on November 11, 2021, is located in Shandong Province, China [1] - The company's main business involves the research, production, and sales of special glass, focusing on the development and application of borosilicate glass [1] - The revenue composition of Linuo Pharmaceutical includes 57.02% from heat-resistant glass, 40.74% from pharmaceutical glass, and 2.24% from material sales and others [1] Financial Performance - As of September 30, 2025, Linuo Pharmaceutical reported a total revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2] - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, the number of shareholders for Linuo Pharmaceutical increased by 58.60% to 17,600 [2] - The average number of circulating shares per shareholder decreased by 36.94% to 13,571 shares [2] - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B and Green High Dividend Preferred Mixed A, among others [2]

Core Insights - Linuo Pharmaceutical Packaging Co., Ltd. experienced a stock price increase of 1.00% on November 11, with a trading volume of 55.33 million yuan [1] - The company reported a financing net purchase of 378,300 yuan on the same day, with a total financing and securities balance of 134 million yuan [1] - The company’s main business includes the research, production, and sales of special glass, with a revenue composition of 57.02% from heat-resistant glass and 40.74% from medicinal glass [1] Financing and Trading Data - On November 11, Linuo Pharmaceutical had a financing purchase of 6.68 million yuan, with a current financing balance of 134 million yuan, representing 3.25% of its market capitalization [1] - The financing balance is above the 60th percentile level over the past year, indicating a relatively high position [1] - There were no short sales or repayments on the same day, with the short selling balance also at zero, placing it in the 90th percentile level over the past year [1] Financial Performance - For the period from January to September 2025, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2] - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2] Shareholder Composition - As of September 30, 2025, the number of shareholders increased by 58.60% to 17,600, while the average circulating shares per person decreased by 36.94% to 13,571 shares [2] - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B and Green High Dividend Preferred Mixed A, among others [2]

Group 1 - The core viewpoint of the news highlights the financial performance and stock trading activities of Linuo Pharmaceutical Packaging Co., Ltd. as of November 6, 2023, indicating a mixed outlook with a slight increase in stock price and notable financing activities [1][2] Group 2 - As of November 6, 2023, Linuo Pharmaceutical's stock price increased by 0.35%, with a trading volume of 45.19 million yuan [1] - The financing buy-in amount for Linuo Pharmaceutical on the same day was 6.55 million yuan, while the financing repayment was 3.89 million yuan, resulting in a net financing buy-in of 2.65 million yuan [1] - The total financing and securities balance for Linuo Pharmaceutical reached 142 million yuan, accounting for 3.47% of its market capitalization, which is above the 60th percentile level over the past year [1] - On the securities lending side, there were no shares sold or repaid on November 6, 2023, with a securities lending balance of 0, indicating a high level of inactivity in this area [1] Group 3 - As of September 30, 2023, the number of shareholders for Linuo Pharmaceutical increased by 58.60% to 17,600, while the average circulating shares per person decreased by 36.94% to 13,571 shares [2] - For the period from January to September 2023, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2] - Since its A-share listing, Linuo Pharmaceutical has distributed a total of 139 million yuan in dividends, with 92.18 million yuan distributed over the past three years [2] - As of September 30, 2023, new institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B and Green High Dividend Preferred Mixed A, among others [2]

Core Viewpoint - The stock price of Linuo Pharmaceutical Packaging has experienced a decline recently, despite a year-to-date increase, indicating potential volatility in the market [1][2]. Company Overview - Linuo Pharmaceutical Packaging Co., Ltd. is located in Shandong Province, established on March 1, 2002, and listed on November 11, 2021. The company specializes in the research, production, and sales of specialty glass, focusing on borosilicate glass development and application [2]. - The main business revenue composition includes heat-resistant glass (57.02%), pharmaceutical glass (40.74%), and other material sales (2.24%) [2]. Stock Performance - Year-to-date, the stock price has increased by 14.72%, but it has decreased by 2.62% over the last five trading days, 0.12% over the last 20 days, and 20.26% over the last 60 days [2]. - As of October 29, the stock price was reported at 17.12 CNY per share, with a market capitalization of 4.093 billion CNY [1]. Financial Performance - For the period from January to September 2025, Linuo Pharmaceutical Packaging reported a revenue of 721 million CNY, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.8823 million CNY, down 27.80% year-on-year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 58.60% to 17,600, while the average circulating shares per person decreased by 36.94% to 13,571 shares [2]. - The company has distributed a total of 139 million CNY in dividends since its A-share listing, with 92.177 million CNY distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, new institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B (holding 3.8 million shares), Green High Dividend Preferred Mixed A (holding 3.1433 million shares), and Yuanxin Yongfeng Pharmaceutical Health A (holding 1.62 million shares) [3].

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in stock performance, with a year-to-date increase of 19.08% and a recent decline over the past 60 days of 17.88% [2] Company Overview - Linuo Pharmaceutical Packaging, established on March 1, 2002, and listed on November 11, 2021, is located in Shandong Province, China [2] - The company specializes in the research, production, and sales of specialty glass, focusing on borosilicate glass development and application [2] - Revenue composition includes heat-resistant glass (57.02%), pharmaceutical glass (40.74%), and other material sales (2.24%) [2] - The company operates within the pharmaceutical and biological industry, specifically in medical devices and consumables [2] Financial Performance - For the first half of 2025, Linuo Pharmaceutical reported revenue of 499 million yuan, a year-on-year decrease of 11.07% [2] - The net profit attributable to the parent company was approximately 40.97 million yuan, reflecting a year-on-year decline of 20.12% [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 17.08% to 11,100 [2] - The average number of circulating shares per shareholder decreased by 12.16% to 21,522 shares [2] - Cumulative cash dividends since the company's A-share listing amount to 139 million yuan, with 92.18 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Guotai Junan Value Advantage Flexible Allocation Mixed Fund, which holds 5.90 million shares, a decrease of 1.55 million shares from the previous period [3] - Guotai Junan Innovation Growth Mixed Fund holds 2.87 million shares, down by 530,000 shares [3] - Guotai Junan Pharmaceutical Health Stock A is a new shareholder with 2.79 million shares [3]

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. has experienced fluctuations in financing and stock performance, with a notable decrease in revenue and net profit in the first half of 2025 [1][2]. Financing and Stock Performance - On October 9, Linuo Pharmaceutical's stock rose by 0.29%, with a trading volume of 64.94 million yuan [1]. - The financing buy-in amount for Linuo Pharmaceutical on the same day was 7.58 million yuan, while the financing repayment was 13.31 million yuan, resulting in a net financing outflow of 5.72 million yuan [1]. - As of October 9, the total financing and securities lending balance for Linuo Pharmaceutical was 161 million yuan, accounting for 3.90% of its market capitalization, indicating a high level compared to the past year [1]. Company Overview - Linuo Pharmaceutical, established on March 1, 2002, and listed on November 11, 2021, is located in Shandong Province, China [1]. - The company specializes in the research, production, and sales of specialty glass, focusing on the development and application of borosilicate glass [1]. - The revenue composition of Linuo Pharmaceutical includes heat-resistant glass (57.02%), pharmaceutical glass (40.74%), and other material sales (2.24%) [1]. Financial Performance - As of June 30, 2025, Linuo Pharmaceutical had 11,100 shareholders, an increase of 17.08% from the previous period [2]. - The company reported a revenue of 499 million yuan for the first half of 2025, a year-on-year decrease of 11.07%, and a net profit attributable to shareholders of 40.97 million yuan, down 20.12% year-on-year [2]. - Since its A-share listing, Linuo Pharmaceutical has distributed a total of 139 million yuan in dividends, with 92.18 million yuan distributed over the past three years [2]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders of Linuo Pharmaceutical, Guotai Junan's value advantage flexible allocation mixed fund held 5.90 million shares, a decrease of 1.55 million shares from the previous period [2]. - Guotai Junan's innovative growth mixed fund held 2.87 million shares, down by 530,000 shares, while Guotai Junan's pharmaceutical health stock A fund entered as a new shareholder with 2.79 million shares [2].